How The Prostate Cancer Market Will Look Over Next Decade

30 Jan 2018

As generic competition to J&J's Zytiga starts to line up ahead of possible launches in October, Datamonitor Healthcare has been weighing up the prostate cancer therapy space and seeing where the future competition will come from for Pfizer and Astellas' market leader Xtandi.

Consultation — The prostate cancer therapy market is set to keep growing • Source: Shutterstock

Now that Johnson & Johnson's blockbuster Zytiga (abiraterone acetate) is to be hit by generic competition later this year in the US, analysts at Datamonitor Healthcare have been looking at the next drivers of the prostate cancer market.

Earlier this month, the US Patent and Trademark Office's Patent Trial and Appeal Board (PTAB) invalidated the composition and method...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

02 Jul 2025

• By Alaric DeArment

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

02 Jul 2025

• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

In Brief: Sanofi Cements Support For Adagene

01 Jul 2025

• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.